Drugs / 177Lu-PSMA-617
177Lu-PSMA-617
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | PLUVICTO | — | 2025-03-28 – 2026-07-31 | fda.gov ↗ |
| Approved | EU (EMA) | Pluvicto | — | 2022-12-09 | europa.eu ↗ |
| Approved | US (FDA) | PLUVICTO | — | 2022-03-23 | fda.gov ↗ |
Trials 68 · started per year
today
US approved 2022
EU approved 2022
1
1
3
1
4
6
4
7
13
16
11
201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06516510 | Oct 2024 → Aug 2025 | metastatic prostate carcinoma | Blue Earth Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07682649 | Aug 2026 → Aug 2027 expected | castration-resistant prostate carcinoma | University of Michigan Rogel Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07145177 | Mar 2026 → Oct 2028 expected | metastatic prostate carcinoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 1 | NCT07219147 | Mar 2026 → Jul 2028 expected | prostate adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07223034 | Oct 2025 → Oct 2027 expected | IDH-wildtype glioblastoma, diffuse astrocytoma, diffuse glioma, H3 G34 mutant, diffuse midline glioma, H3 K27-altered +1 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07054346 | Jul 2025 → Apr 2027 expected | prostate carcinoma | Thomas Hope | Recruiting | No outcome recorded |
| Phase 1 | NCT06531499 | Nov 2024 → Nov 2028 expected | prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06379217 | Jul 2024 → Aug 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06303713 | May 2024 → Oct 2026 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05162573 | Dec 2021 → Sep 2025 | prostate neoplasm | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT05079698 | Oct 2021 → Oct 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04886986 | Jun 2021 → Dec 2027 expected | prostate cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1 | NCT03805594 | May 2019 → Jan 2024 | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT06388369 | Aug 2025 → Mar 2026 | prostate cancer | University Hospital, Essen | Terminated | No outcome recorded |
| Phase 1/2 | NCT06574880 | May 2025 → Sep 2026 expected | prostate cancer | Angela Y. Jia, MD PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05682443 | Dec 2023 → Nov 2026 expected | prostate carcinoma | OncoC4, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05340374 | Jul 2022 → Jun 2026 overdue | castration-resistant prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05113537 | Jul 2022 → May 2026 overdue | castration-resistant prostate carcinoma, prostate adenocarcinoma | Vadim S Koshkin | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04430192 | Aug 2020 → Dec 2022 overdue | prostate neoplasm | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03828838 | Jul 2018 → Nov 2019 | prostate neoplasm | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03545165 | Apr 2018 → Jul 2020 | prostate cancer | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT03042468 | Dec 2016 → Sep 2021 overdue | prostate cancer | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT07698535 | Dec 2026 → Jul 2029 expected | prostate adenocarcinoma | University of Washington | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07650240 | Jul 2026 → Dec 2030 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07550517 | Jul 2026 → Jul 2032 expected | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06852820 | Jun → Dec 2026 expected | hepatocellular carcinoma | Melissa Lumish | Recruiting | No outcome recorded |
| Phase 2 | NCT06783348 | Apr 2026 → Jan 2028 expected | clear cell renal carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 2 | NCT07150715 | Dec 2025 → Oct 2030 expected | prostate adenocarcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06894511 | Sep 2025 → Oct 2026 expected | prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07025512 | Aug 2025 → May 2026 | anemia, castration-resistant prostate carcinoma, thrombocytopenia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT06964958 | Jul 2025 → Dec 2026 expected | clear cell renal carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06738303 | Jul 2025 → Dec 2026 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07047118 | Jul 2025 → Jul 2027 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06972628 | May 2025 → Apr 2027 expected | prostate carcinoma | Ebrahim S Delpassand | Recruiting | No outcome recorded |
| Phase 2 | NCT06526299 | Apr 2025 → Dec 2027 expected | castration-resistant prostate carcinoma | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06866938 | Apr 2025 → Apr 2027 expected | castration-resistant prostate carcinoma | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 2 | NCT06798558 | Mar 2025 → Mar 2029 expected | prostate adenocarcinoma | Hackensack Meridian Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06632977 | Feb 2025 → Apr 2030 expected | castration-resistant prostate carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT06449781 | Jan 2025 → Nov 2030 expected | prostate cancer | Maria Sklodowska-Curie National Research Institute of Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT06288113 | Aug 2024 → Jan 2027 expected | castration-resistant prostate carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06216249 | Aug 2024 → Dec 2027 expected | prostate carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06200103 | May 2024 → Dec 2029 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06004661 | Apr 2024 → Dec 2026 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05849298 | Jan 2024 → Dec 2026 expected | prostate neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06199453 | Jan 2024 → Nov 2027 | adenoid cystic carcinoma | Maria Sklodowska-Curie National Research Institute of Oncology | Withdrawn | No outcome recorded |
| Phase 2 | NCT05766371 | Dec 2023 → May 2027 expected | prostate carcinoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT06084338 | Dec 2023 → Nov 2027 expected | prostate cancer | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT05670106 | May 2023 → May 2024 | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05658003 | May 2023 → Dec 2024 overdue | prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03454750 | Oct 2022 → May 2024 | castration-resistant prostate carcinoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT05150236 | Apr 2022 → Aug 2024 | prostate cancer, urinary system neoplasm | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Unknown | No outcome recorded |
| Phase 2 | NCT04663997 | Aug 2021 → Aug 2025 overdue | prostate cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04419402 | Aug 2020 → Apr 2024 overdue | castration-resistant prostate carcinoma | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04443062 | Jul 2020 → Apr 2025 | prostate cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04343885 | Apr 2020 → Mar 2026 overdue | prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03042312 | Jul 2017 → Jan 2020 | castration-resistant prostate carcinoma | Endocyte | Terminated | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT06959433 | May 2026 → Feb 2028 expected | kidney cancer | Ankara University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07200830 | Mar 2026 → Sep 2034 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06496581 | Sep 2024 → Feb 2033 expected | metastatic prostate carcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 3 | NCT06320067 | Jun 2024 → Apr 2031 expected | metastatic prostate carcinoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT05939414 | Mar 2024 → Apr 2028 expected | prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT04689828 | Jun 2021 → Oct 2022 overdue | prostate neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04720157 | Jun 2021 → Jan 2025 overdue | prostate neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03511664 | May 2018 → Jan 2021 | prostate cancer | Endocyte | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07677566 | Jul 2026 → Jul 2027 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05803941 | Aug 2023 → Jul 2033 expected | prostate cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04825652 | — | castration-resistant prostate carcinoma | Advanced Accelerator Applications | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06943495 Comparator | Aug 2025 → Mar 2029 expected | castration-resistant prostate carcinoma | Jean-Mathieu Beauregard | Recruiting | No outcome recorded |
| Phase 1 | NCT06095089 Background | Nov 2023 → Jun 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05613894 Background | Jul 2023 → Dec 2026 | prostate carcinoma | University of Utah | Suspended | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07206056 Comparator | Oct 2025 → Nov 2029 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06329830 Background | Oct 2024 → Oct 2026 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Baptist Health South Florida | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06145633 Background | Sep 2024 → Dec 2026 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06855277 Comparator | Jul 2025 → Sep 2028 expected | prostate cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Press releases naming this drug 18 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | Novartis Pharmaceuticals | FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease novartis.com ↗ |
| 2026-05-31 | Novartis Pharmaceuticals | Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer novartis.com ↗ |
| 2026-05-17 | Novartis Pharmaceuticals | New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer novartis.com ↗ |
| 2026-02-24 | Novartis Pharmaceuticals | New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer novartis.com ↗ |
| 2025-10-19 | Novartis Pharmaceuticals | PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer novartis.com ↗ |
| 2025-06-02 | Novartis Pharmaceuticals | Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer novartis.com ↗ |
| 2025-03-28 | Novartis Pharmaceuticals | FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer novartis.com ↗ |
| 2024-01-05 | Novartis Pharmaceuticals | Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis novartis.com ↗ |
| 2023-10-26 | Novartis Pharmaceuticals | Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers novartis.com ↗ |
| 2023-10-23 | Novartis Pharmaceuticals | Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting novartis.com ↗ |
| 2022-12-13 | Novartis Pharmaceuticals | Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer novartis.com ↗ |
| 2022-12-05 | Novartis Pharmaceuticals | Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer novartis.com ↗ |
| 2022-10-14 | Novartis Pharmaceuticals | Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer novartis.com ↗ |
| 2022-03-23 | Novartis Pharmaceuticals | Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer novartis.com ↗ |
| 2021-09-17 | Novartis Pharmaceuticals | Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 novartis.com ↗ |
| 2021-06-24 | Novartis Pharmaceuticals | Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine novartis.com ↗ |
| 2021-06-03 | Novartis Pharmaceuticals | Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study novartis.com ↗ |
| 2021-03-23 | Novartis Pharmaceuticals | Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer novartis.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 87 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu PSMA 617 | “PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when...” NCT06496581 ↗36“Five participants will receive a single dose of 177Lu-PSMA-617 radioligand therapy intravenously (IV), five participants will receive a single dose of 177Lu-PSMA-617...” NCT07054346 ↗ “The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate...” NCT06852820 ↗ “(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer...” PMID 39293462 ↗ Sep 2024 “Background Lutetium 177 (177Lu) prostate-specific membrane antigen (PSMA)-617 SPECT/CT has demonstrated promise as a response biomarker for 177Lu-PSMA-617 therapy.” PMID 42048586 ↗ Apr 2026 “177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body.” NCT04663997 ↗ “BACKGROUND: 177Lu-PSMA-617 is a radioligand therapy targeting cells expressing prostate-specific membrane antigen (PSMA).” PMID 41764712 ↗ Mar 2026 “injection of 3.7-5.5 GBq of 177Lu-PSMA-617 repeated four times at interval of 8 weeks.” PMID 32430583 ↗ May 2020 “(177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC.” NCT05613894 ↗ “177Lu-PSMA-617 is a nuclear medicine therapy.” NCT06320067 ↗ |
| Known as | 177Lu-DOTA-PSMA-617 | “177Lu-DOTA-PSMA-617 (177Lu-PSMA-617) is a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioligand for radionuclide...” PMID 31595044 ↗ Oct 2019 |
| Known as | 177Lu-PSMA-617 also referred to as 177Lu-PSMA | “177Lu-PSMA-617 also referred to as 177Lu-PSMA” NCT04343885 ↗ |
| Known as | 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA | “177Lutetium -PSMA 617 also referred to as 177Lu-PSMA” NCT04419402 ↗1“177Lutetium -PSMA 617 also referred to as 177Lu-PSMA” NCT05150236 ↗ |
| Known as | 177Lutetium-PSMA-617 | “The goal of this study is to examine if a new drug treatment called 177Lutetium-PSMA-617, hereafter referred as 177Lu-PSMA-617, which holds the active ingredient...” NCT06783348 ↗ |
| Known as | [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 | “[177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 is a standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated...” PMID 39978808 ↗ Apr 20251“[177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 (177Lu-PSMA-617) is a novel treatment for metastatic castration-resistant prostate cancer.” PMID 41926960 ↗ Apr 2026 |
| Known as | [177Lu]Lu-PSMA-617 | “BACKGROUND: Dosimetry in [177Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol to...” PMID 36692682 ↗ Jan 20239“Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p):...” PMID 39956124 ↗ Feb 2025 “In HCC, a recent preclinical study demonstrated that radioligand therapy using \[177Lu\]Lu-PSMA-617 and \[177Lu\]Lu-EB-PSMA-617 effectively suppressed tumor growth and...” NCT06852820 ↗ “lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) significantly improved radiographic progression-free survival compared with change of androgen receptor pathway inhibitor (ARPI)” PMID 40441170 ↗ May 2025 “[177Lu]Lu-PSMA-617 radiopharmaceutical therapy has been approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)” PMID 40876952 ↗ Oct 2025 “2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals” NCT06388369 ↗ |
| Known as | [177Lu]Lu-PSMA-617 (AAA617) | “[177Lu]Lu-PSMA-617 (AAA617)” NCT06855277 ↗ |
| Known as | AAA617 | “The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel or \[177Lu\]Lu-PSMA-617 (AAA617).” NCT06855277 ↗ |
| Known as | Lu-177 PSMA | “Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)” NCT03828838 ↗ |
| Known as | Lu-177 PSMA-617 | “2 cycles of Lu-177-PSMA-617 (PluvictoⓇ) administered at 6-week intervals before prostatectomy in patients with high risk localized prostate cancer.” NCT06798558 ↗ |
| Known as | Lu-177 vipivotide tetraxetan | “The VISION study was a phase 3 trial investigating the efficacy and safety of 177Lu-PSMA-617 (Lu-177 vipivotide tetraxetan) with standard of care in patients with previously...” NCT06852820 ↗ |
| Known as | Lu-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04419402 ↗ |
| Known as | Lu-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06852820 ↗ |
| Known as | lutetium (177Lu) vipivotide tetraxetan | “This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of...” NCT06004661 ↗ |
| Known as | Lutetium Lu 177 vipivotide tetraxetan | “The goal of this clinical trial is to assess if a personalized regime of 177Lu-PSMA-617 (Lutetium Lu 177 vipivotide tetraxetan, also known as Pluvicto) is feasible and safe in...” NCT06943495 ↗ |
| Known as | Lutetium Lu 177-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03805594 ↗ |
| Known as | Lutetium-177-PSMA-617 | “Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study.” PMID 33883176 ↗ Apr 2021 |
| Known as | Pluvicto | “The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer...” NCT06972628 ↗5“The goal of this clinical trial is to assess if a personalized regime of 177Lu-PSMA-617 (Lutetium Lu 177 vipivotide tetraxetan, also known as Pluvicto) is feasible and safe in...” NCT06943495 ↗ “Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator” NCT07206056 ↗ “lutetium (177Lu) vipivotide tetraxetan (Pluvicto®)” NCT06516510 ↗ “[177Lu]Lu-PSMA-617 (Pluvicto, Novartis)” NCT06866938 ↗ |
| Known as | PluvictoⓇ | “2 cycles of Lu-177-PSMA-617 (PluvictoⓇ) administered at 6-week intervals before prostatectomy in patients with high risk localized prostate cancer.” NCT06798558 ↗ |
| Known as | vipivotide tetraxetan | “In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) improved radiographic...” PMID 37269841 ↗ Jun 20231“lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) significantly improved radiographic progression-free survival compared with change of androgen receptor pathway inhibitor (ARPI)” PMID 40441170 ↗ May 2025 |
| Action | Inhibit | “which is an inhibitor capable of binding to the domain of PSMA.” NCT03042312 ↗ |
| Modality | Other / unclassified | “Radioligand therapy (RLT) with 177Lu-PSMA-617 is a promising option” PMID 32430583 ↗ May 2020 |
| Route | Intravenous | “repeated intravenous (i.v.) injection” NCT03042312 ↗ |